Intravenous leiomyomatosis is a rare benign neoplasm originating from smooth muscle cells. Although histopathologically benign, its behavior may be
aggressive and fatal outcomes can occur. However, it is very difficult to diagnose this entity, and intravenous leiomyomatosis is usually only suspected
intraoperatively or after pathological analysis. In this article, we presented an interesting case of intravenous leiomyomatosis who was diagnosed intraoperatively and complicated with massive bleeding. Subsequent histopathological and immunohistochemical examination confirmed the diagnosis
as intravenous leiomyomatosis.
|
OBJECTIVE: Iodine deficiency is a commonly seen problem and associated with pregnancy complications. In this study, we aimed to evaluate urinary iodine status in pregnant women with hyperemesisgravidarumSTUDY DESIGN: A total of 121 women experiencing singleton pregnancies between 6 and 18 weeksof gestation were included in the study. The participants were divided into two groups; group 1 comprised 81 healthy pregnant women, and group 2 comprised 40 pregnant women with HyperemesisGravidarum.RESULTS: Urinary iodine levels were found to be significantly higher in healthy pregnant women thanwomen with Hyperemesis Gravidarum (p=0.008). Urinary iodine was significantly correlated with the urinary ketone (r= -0.252, p=0.005) and FT3 (r= -0.190, p=0.037).CONCLUSION: In pregnant women with hyperemesis gravidarum, oxidative stress was increased, urinary iodine levels were significantly low and negatively correlated with disease severity. Thus, ıodine replacement might be essential to prevent pregnancy complications.
|
Caner ÇAKIR ,
Fatih KILIÇ ,
Rıza DUR ,
Dilek YÜKSEL ,
Mehmet ÜNSAL ,
Vakkas KORKMAZ ,
Çiğdem KILIÇ ,
Günsu Kimyon CÖMERT ,
Nurettin BORAN ,
Osman TÜRKMEN ,
Sevgi KOÇ ,
Ahmet TURAN
Objective: This study aimed to evaluate neoadjuvant chemotherapy (NACT) for locally advanced stage cervical carcinoma. Materials and Methods: Data of 43 patients with locally advanced cervical carcinoma who had NACT were reviewed. NACT protocols implemented included cisplatin/5-fluorauracil, cisplatin/UFT, and carboplatin/paclitaxel. After NACT, the patients were re-examined, and patients who had a tumor size ≤40 mm underwent Piver-Rutledge type III radical hysterectomy, while other patients received radiotherapy. Following NACT, clinical responses were assessed according to the criteria of the World Health Organization. Results: The mean age of the patients was 49.4 years, and the median follow-up duration was 48 (range, 5-228) months. The median tumor sizes were 50 and 30 mm before and after NACT, respectively. Complete clinical response was observed in 4 (9.3%) patients, partial clinical response in 8 (18.6%), and pathologic complete response in 3 (6.9%). Stable disease was noted in 30 (69.9%) patients and progression in 1 (2.3%) patient. After NACT, 31 patients have undergone radical surgical procedures. The 5-year disease-free survival rate was 72%, and the 5-year disease-specific survival rate was 91%. Age, International Federation of Gynaecology and Obstetrics 2009 stage, histopathologic type, NACT protocol, rate of decrease in tumor size after NACT, clinical response, number of courses, tumor size before NACT, tumor size after NACT, and lymph node metastasis were not associated with disease-free survival. Conclusion: Following NACT, a significant reduction in tumor dimension was observed, and the probability of radical surgery is increased. However, clinical response was not predictive of survival.
|
Background: Comparison of predictive values of complete blood count inflammatory parameters and serum CA-125 levels in the differential diagnosis of patients with epithelial ovarian tumor (EOTs) diagnosed in the reproductive period. Materials: In this study, 105 women patients in the reproductive period were retrospectively analyzed. The patients included were examined in terms of clinical, laboratory and pathological features. Results: The mean age of the patients was 41.5 ± 8.6 years and BMI was 28.6 ± 5.8 kg/m2. Of the whole study population, 54 (51.5%) were benign EOTs, 18 (17.1%) were borderline EOTs and 33 (31.4%) were malignant EOTs. When comparing these three tumor groups, a significant difference was found in terms of serum CA-125 [14.7 U/mL (2.7-238.6) vs 60.2 U/mL (7.8 – 557) vs 416.5 U/mL (2.4-7695), p<0.001, respectively], platelet count [294 x103/ μL (133-744) vs 303, x103/ μL (160-468) vs 383 x103/ μL (128-725), p = 0.018, respectively], neutrophil count [4.2, x103/ μL (1.9 -8.9) vs 4.9 x103/ μL (2.6- 10.9) vs 5.1 x103/ μL (2.2 – 10.7), p = 0.012], neutrophil-to-lymphocyte ratio (NLR) [2.1 (0.1-8.2) vs 2.6 (1.2 – 5.9) vs 3.1 (1-6.8), p = 0.021, respectively] and platelet-to-lymphocyte ratio (PLR) [154.4 (82.1-658.4) vs 168.1 (91.1-377.8) vs 201.5 (29.6-499.2), p = 0.008, respectively] values. In the ROC analyses, serum CA-125 levels (AUC= 0.818, p <0.001), platelet count (AUC= 0.673, p = 0.005) and PLR (AUC= 0.690, p = 0.002) values significantly predicted malignant EOTs. Conclusion: Preoperative platelet count, neutrophil count and PLR predict epithelial ovarian cancers significantly. However, diagnostic predictive values of all three parameters are lower than CA-125. Therefore, CA-125 is still the most valuable serum biochemical marker that can be used in the preoperative differential diagnosis of EOTs.
|
